The Role of Biomarkers in Clinical Trials for Alzheimer Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Matthews, 2003, Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease., Am J Geriatr Psychiatry, 11, 146, 10.1097/00019442-200303000-00005
Frank, 2003, Biological markers for therapeutic trials in Alzheimers disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimers disease., Neurobiol Aging, 24, 521, 10.1016/S0197-4580(03)00002-2
Silbert, 2003, Changes in premorbid brain volume predict Alzheimers disease pathology., Neurology, 61, 487, 10.1212/01.WNL.0000079053.77227.14
Fox, 2000, Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects., Arch Neurol, 57, 339, 10.1001/archneur.57.3.339
Alexander, 2002, Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimers disease treatment studies., Am J Psychiatry, 159, 738, 10.1176/appi.ajp.159.5.738
Minoshima, 1995, A diagnostic approach in Alzheimers disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET., J Nucl Med, 36, 1238
Moriearty, 1999, Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimers disease., Methods Find Exp Clin Pharmacol, 21, 549, 10.1358/mf.1999.21.8.794837
Kaye, 1997, Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia., Neurology, 48, 1297, 10.1212/WNL.48.5.1297
Jack, 1998, Rate of medial temporal lobe atrophy in typical aging and Alzheimers disease., Neurology, 51, 993, 10.1212/WNL.51.4.993
Laakso, 2000, Hippocampus in Alzheimers disease: a 3-year follow-up MRI study., Biol Psychiatry, 47, 557, 10.1016/S0006-3223(99)00167-5
Bradley, 2002, Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimers disease., Br J Radiol, 75, 506, 10.1259/bjr.75.894.750506
Scahill, 2002, Mapping the evolution of regional atrophy in Alzheimers disease: unbiased analysis of fluid-registered serial MRI., Proc Natl Acad Sci USA, 99, 4703, 10.1073/pnas.052587399
Smith, 2002, Accurate, robust, and automated longitudinal and cross-sectional brain change analysis., Neuroimage, 17, 479, 10.1006/nimg.2002.1040
Teipel, 2002, Progression of corpus callosum atrophy in Alzheimer disease., Arch Neurol, 59, 243, 10.1001/archneur.59.2.243
Wang, 2002, MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimers disease and normal aging., Magn Reson Imaging, 20, 41, 10.1016/S0730-725X(02)00472-1
Du, 2003, Atrophy rates of entorhinal cortex in AD and normal aging., Neurology, 60, 481, 10.1212/01.WNL.0000044400.11317.EC
Schott, 2003, Assessing the onset of structural change in familial Alzheimers disease., Ann Neurol, 53, 181, 10.1002/ana.10424
Du, 2004, Higher atrophy rate of entorhinal cortex than hippocampus in AD., Neurology, 62, 422, 10.1212/01.WNL.0000106462.72282.90
Jack, 2004, Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD., Neurology, 62, 591, 10.1212/01.WNL.0000110315.26026.EF
Thompson, 2004, Mapping hippocampal and ventricular change in Alzheimer disease., Neuroimage, 22, 1754, 10.1016/j.neuroimage.2004.03.040
Jack, 2003, MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD., Neurology, 60, 253, 10.1212/01.WNL.0000042480.86872.03
Fox, 2005, Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease., Neurology, 64, 1563, 10.1212/01.WNL.0000159743.08996.99
Silverman, 2001, Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome., JAMA, 286, 2120, 10.1001/jama.286.17.2120
Arnaiz, 2001, Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment., Neuroreport, 12, 851, 10.1097/00001756-200103260-00045
Drzezga, 2003, Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimers disease: a PET follow-up study., Eur J Nucl Med Mol Imaging, 30, 1104, 10.1007/s00259-003-1194-1
Berent, 1999, Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimers disease., J Psychiatr Res, 33, 7, 10.1016/S0022-3956(98)90048-6
Chetelat, 2003, Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimers disease?, Neurology, 60, 1374, 10.1212/01.WNL.0000055847.17752.E6
Klunk, 2004, Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B., Ann Neurol, 55, 306, 10.1002/ana.20009
Mathis, 2005, Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies., Arch Neurol, 62, 196, 10.1001/archneur.62.2.196
Ashburner, 2003, Computer-assisted imaging to assess brain structure in healthy and diseased brains., Lancet Neurol, 2, 79, 10.1016/S1474-4422(03)00304-1
Chetelat, 2005, Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study., Neuroimage, 27, 934, 10.1016/j.neuroimage.2005.05.015
Senjem, 2005, Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease., Neuroimage, 26, 600, 10.1016/j.neuroimage.2005.02.005
Meyerhoff, 1994, Axonal injury and membrane alterations in Alzheimers disease suggested by in vivo proton magnetic resonance spectroscopic imaging., Ann Neurol, 36, 40, 10.1002/ana.410360110
Chao, 2005, Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients., Neurology, 64, 282, 10.1212/01.WNL.0000149638.45635.FF
Jahng, 2003, Improved perfusion-weighted MRI by a novel double inversion with proximal labeling of both tagged and control acquisitions., Magn Reson Med, 49, 307, 10.1002/mrm.10339
Jahng, 2005, Human brain: reliability and reproducibility of pulsed arterial spin-labeling perfusion MR imaging., Radiology, 234, 909, 10.1148/radiol.2343031499
Johnson, 2005, Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience., Radiology, 234, 851, 10.1148/radiol.2343040197
Andreasen, 2001, Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice., Arch Neurol, 58, 373, 10.1001/archneur.58.3.373
Blennow, 1993, Low frequency of post-lumbar puncture headache in demented patients., Acta Neurol Scand, 88, 221
Andreasen, 1999, Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset alzheimer disease and stability during the course of disease., Arch Neurol, 56, 673, 10.1001/archneur.56.6.673
Mehta, 2001, Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease., Neurosci Lett, 304, 102, 10.1016/S0304-3940(01)01754-2
Mayeux, 2003, Plasma A[beta]40 and A[beta]42 and Alzheimers disease: relation to age, mortality, and risk., Neurology, 61, 1185, 10.1212/01.WNL.0000091890.32140.8F
Blennow, 2004, Cerebrospinal fluid protein biomarkers for Alzheimers disease., Neurorx, 1, 213, 10.1602/neurorx.1.2.213
Hampel, 2004, Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study., Arch Gen Psychiatry, 61, 95, 10.1001/archpsyc.61.1.95
Ishiguro, 1999, Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimers disease., Neurosci Lett, 270, 91, 10.1016/S0304-3940(99)00476-0
Kohnken, 2000, Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimers disease patients., Neurosci Lett, 287, 187, 10.1016/S0304-3940(00)01178-2
Vanmechelen, 2000, Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization., Neurosci Lett, 285, 49, 10.1016/S0304-3940(00)01036-3
Zetterberg, 2003, Cerebrospinal fluid markers for prediction of Alzheimers disease., Neurosci Lett, 352, 67, 10.1016/j.neulet.2003.08.011
Hampel, 2001, Tracking of Alzheimers disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231., Ann Neurol, 49, 545, 10.1002/ana.111
Clark, 2003, Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?, Arch Neurol, 60, 1696, 10.1001/archneur.60.12.1696
Maddalena, 2003, Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42., Arch Neurol, 60, 1202, 10.1001/archneur.60.9.1202
Hu, 2002, Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimers disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay., Am J Pathol, 160, 1269, 10.1016/S0002-9440(10)62554-0
Pratico, 2004, Lipid peroxidation and oxidative imbalance: early functional events in Alzheimers disease., J Alzheimers Dis, 6, 171, 10.3233/JAD-2004-6209
Pratico, 2000, Oxidative injury in diseases of the central nervous system: focus on Alzheimers disease., Am J Med, 109, 577, 10.1016/S0002-9343(00)00547-7
Pratico, 2002, Alzheimers disease and oxygen radicals: new insights., Biochem Pharmacol, 63, 563, 10.1016/S0006-2952(01)00919-4
Pratico, 2001, The isoprostanes in biology and medicine., Trends Endocrinol Metab, 12, 243, 10.1016/S1043-2760(01)00411-8
Pratico, 1998, Increased F2-isoprostanes in Alzheimers disease: evidence for enhanced lipid peroxidation in vivo., FASEB J, 12, 1777, 10.1096/fasebj.12.15.1777
Pratico, 2000, Increased 8,12-iso-iPF2alpha-VI in Alzheimers disease: correlation of a noninvasive index of lipid peroxidation with disease severity., Ann Neurol, 48, 809, 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9
Yao, 2003, Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia., Neurology, 61, 475, 10.1212/01.WNL.0000070185.02546.5D
Grossman, 2005, Cerebrospinal fluid profile in frontotemporal dementia and Alzheimers disease., Ann Neurol, 57, 721, 10.1002/ana.20477
Wisniewski, 1985, Occurrence of neuropathological changes and dementia of Alzheimers disease in Downs syndrome., Ann Neurol, 17, 278, 10.1002/ana.410170310
Griffin, 1989, Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease., Proc Natl Acad Sci USA, 86, 7611, 10.1073/pnas.86.19.7611
Griffin, 1998, Life-long overexpression of S100beta in Downs syndrome: implications for Alzheimer pathogenesis., Neurobiol Aging, 19, 401, 10.1016/S0197-4580(98)00074-8
Royston, 1999, Overexpression of S100beta in Downs syndrome: correlation with patient age and with beta-amyloid deposition., Neuropathol Appl Neurobiol, 25, 387, 10.1046/j.1365-2990.1999.00196.x
Li, 2000, S100beta induction of the proinflammatory cytokine interleukin-6 in neurons., J Neurochem, 74, 143, 10.1046/j.1471-4159.2000.0740143.x
Goldgaber, 1989, Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells., Proc Natl Acad Sci USA, 86, 7606, 10.1073/pnas.86.19.7606
Sheng, 1994, S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques., J Neurosci Res, 39, 398, 10.1002/jnr.490390406
Griffin, 1995, Interleukin-1 expression in different plaque types in Alzheimers disease: significance in plaque evolution., J Neuropathol Exp Neurol, 54, 276, 10.1097/00005072-199503000-00014
Mrak, 1996, Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimers disease., J Neuropathol Exp Neurol, 55, 273, 10.1097/00005072-199603000-00002
Sheng, 1997, Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages., J Neuropathol Exp Neurol, 56, 285, 10.1097/00005072-199703000-00007
Sheng, 1997, Neuritic plaque evolution in Alzheimers disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms., Acta Neuropathol (Berl), 94, 1, 10.1007/s004010050664
Sheng, 1998, Progressive neuronal injury associated with amyloid plaque formation in Alzheimer disease., J Neuropathol Exp Neurol, 57, 714, 10.1097/00005072-199807000-00008
Sheng, 1998, Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimers disease., Neuropathol Appl Neurobiol, 24, 278, 10.1046/j.1365-2990.1998.00122.x
Sheng, 2000, Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo., Exp Neurol, 163, 388, 10.1006/exnr.2000.7393
Sheng, 2001, Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimers disease: potential significance for tau protein phosphorylation., Neurochem Int, 39, 341, 10.1016/S0197-0186(01)00041-9
Li, 2003, Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway., J Neurosci, 23, 1605, 10.1523/JNEUROSCI.23-05-01605.2003
Liu, 2005, S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors., J Neurochem, 92, 546, 10.1111/j.1471-4159.2004.02909.x
Strauss, 1992, Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimers disease patients., Lab Invest, 66, 223
Abraham, 1988, Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimers disease., Cell, 52, 487, 10.1016/0092-8674(88)90462-X
Lee, 1999, Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques., J Neuropathol Exp Neurol, 58, 1163, 10.1097/00005072-199911000-00006
Heneka, 2005, Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice., Brain, 128, 1442, 10.1093/brain/awh452
Morihara, 2005, Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimers models., Neuropsychopharmacology, 30, 1111, 10.1038/sj.npp.1300668
Richartz, 2005, Decline of immune responsiveness: a pathogenetic factor in Alzheimers disease?, J Psychiatr Res, 39, 535, 10.1016/j.jpsychires.2004.12.005
Thal, 1996, A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimers disease., Neurology, 47, 705, 10.1212/WNL.47.3.705
Thal, 2000, A 1-year controlled trial of acetyl-l-carnitine in early-onset AD., Neurology, 55, 805, 10.1212/WNL.55.6.805
Aisen, 2000, A randomized controlled trial of prednisone in Alzheimers disease. Alzheimers Disease Cooperative Study., Neurology, 54, 588, 10.1212/WNL.54.3.588
Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial., JAMA, 289, 2819, 10.1001/jama.289.21.2819
Reines, 2004, Rofecoxib: no effect on Alzheimers disease in a 1-year, randomized, blinded, controlled study., Neurology, 62, 66, 10.1212/WNL.62.1.66
Fox, 2000, Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects., Arch Neurol, 57, 339, 10.1001/archneur.57.3.339
Prince, 2004, APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42., Neurology, 62, 2116, 10.1212/01.WNL.0000128088.08695.05
Galasko, 1998, High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype., Arch Neurol, 55, 937, 10.1001/archneur.55.7.937
Hoglund, 2004, Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins., Arch Neurol, 61, 333, 10.1001/archneur.61.3.333